Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease

Hall, Sara LU ; Janelidze, Shorena LU ; Londos, Elisabet LU ; Leuzy, Antoine LU ; Stomrud, Erik LU orcid ; Dage, Jeffrey L. and Hansson, Oskar LU orcid (2021) In Movement Disorders 36(3). p.767-771
Abstract

Background: Alzheimer's disease co-pathology is common in dementia with Lewy bodies and Parkinson's disease with dementia (Lewy body disease) and can reliably be detected with positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers. Recently developed blood biomarkers are more accessible and less expensive alternatives. Objective: To investigate if plasma phospho-tau217 and phospho-tau181 can detect Alzheimer's pathology in Lewy body disease with dementia. Methods: In this cross-sectional study we investigated plasma phospho-tau217 and phospho-tau181 in 35 patients with Lewy body disease with dementia. Patients underwent tau-PET imaging (18F-RO948). Results: Plasma phospho-tau217 correlated with plasma... (More)

Background: Alzheimer's disease co-pathology is common in dementia with Lewy bodies and Parkinson's disease with dementia (Lewy body disease) and can reliably be detected with positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers. Recently developed blood biomarkers are more accessible and less expensive alternatives. Objective: To investigate if plasma phospho-tau217 and phospho-tau181 can detect Alzheimer's pathology in Lewy body disease with dementia. Methods: In this cross-sectional study we investigated plasma phospho-tau217 and phospho-tau181 in 35 patients with Lewy body disease with dementia. Patients underwent tau-PET imaging (18F-RO948). Results: Plasma phospho-tau217 correlated with plasma phospho-tau181, CSF phospho-tau217 (rs = 0.68, P < 0.001), and negatively with CSF β-amyloid42/40 (rs = −0.52, P = 0.001). Plasma phospho-tau217 and phospho-tau181 correlated with tau-PET signal in the temporal cortex (rs > 0.56, P < 0.001) and predicted abnormal tau-PET status and β-amyloid status (area under the curve > 0.78 and > 0.81, respectively). Conclusion: Plasma phospho-tau might be a useful marker for Alzheimer's co-pathology in Lewy body disease with dementia.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, dementia with Lewy bodies, Parkinson's disease dementia, phospho-tau, plasma
in
Movement Disorders
volume
36
issue
3
pages
767 - 771
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85097227431
  • pmid:33285015
ISSN
0885-3185
DOI
10.1002/mds.28370
language
English
LU publication?
yes
id
2495fc63-92d8-4db4-81c6-30e9668235cd
date added to LUP
2020-12-15 14:34:36
date last changed
2024-06-28 06:21:34
@article{2495fc63-92d8-4db4-81c6-30e9668235cd,
  abstract     = {{<p>Background: Alzheimer's disease co-pathology is common in dementia with Lewy bodies and Parkinson's disease with dementia (Lewy body disease) and can reliably be detected with positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers. Recently developed blood biomarkers are more accessible and less expensive alternatives. Objective: To investigate if plasma phospho-tau217 and phospho-tau181 can detect Alzheimer's pathology in Lewy body disease with dementia. Methods: In this cross-sectional study we investigated plasma phospho-tau217 and phospho-tau181 in 35 patients with Lewy body disease with dementia. Patients underwent tau-PET imaging (<sup>18</sup>F-RO948). Results: Plasma phospho-tau217 correlated with plasma phospho-tau181, CSF phospho-tau217 (r<sub>s</sub> = 0.68, P &lt; 0.001), and negatively with CSF β-amyloid<sub>42/40</sub> (r<sub>s</sub> = −0.52, P = 0.001). Plasma phospho-tau217 and phospho-tau181 correlated with tau-PET signal in the temporal cortex (r<sub>s</sub> &gt; 0.56, P &lt; 0.001) and predicted abnormal tau-PET status and β-amyloid status (area under the curve &gt; 0.78 and &gt; 0.81, respectively). Conclusion: Plasma phospho-tau might be a useful marker for Alzheimer's co-pathology in Lewy body disease with dementia.</p>}},
  author       = {{Hall, Sara and Janelidze, Shorena and Londos, Elisabet and Leuzy, Antoine and Stomrud, Erik and Dage, Jeffrey L. and Hansson, Oskar}},
  issn         = {{0885-3185}},
  keywords     = {{biomarkers; dementia with Lewy bodies; Parkinson's disease dementia; phospho-tau; plasma}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{767--771}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Movement Disorders}},
  title        = {{Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease}},
  url          = {{http://dx.doi.org/10.1002/mds.28370}},
  doi          = {{10.1002/mds.28370}},
  volume       = {{36}},
  year         = {{2021}},
}